Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting Phase II NCT06937931

A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults

A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults — Recruiting • Phase II • Neurology • NCT06937931.

📅 06 Apr 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Phase II
NCT ID
NCT06937931
Start
2025-06-30
Completion
2027-03-26
ClinicaliQ Trial Snapshot
  • A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults — Recruiting • Phase II • Neurology • NCT06937931.
  • Review the linked registry entry for study design, population, endpoints, and operational status.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The purpose of this study is to evaluate the efficacy and safety of the study drug, IPN10200, and to assess how well it works when compared with placebo in treating Cervical Dystonia (CD) in adults. CD can cause a series of abnormalities and symptoms in the head and neck that can lead to neck pain and stiffness, and headaches. CD is believed to involve deep parts within the brain that control movement, but genetic factors, environmental factors, and abnormalities in the brain may also play a role. The usual treatment…

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida (terminated appraisal)
Neurology · 07 May 2026
Oxybutynin is effective for neurogenic detrusor overactivity in patients aged 6+ years with spinal cord injury or spina bifida—consider as first-line antimuscarinic…
View guideline →
Guideline
2022 EAN/EFNS Guidelines on Dementia Diagnosis and Management
Neurology · 30 Mar 2026
This EAN guideline addresses 2022 EAN/EFNS Guidelines on Dementia Diagnosis and Management in Neurology. Use it to review current recommendation wording, eligibility…
View guideline →
Guideline
2023 EAN Guidelines on the Management of Multiple Sclerosis
Neurology · 30 Mar 2026
This EAN guideline addresses 2023 EAN Guidelines on the Management of Multiple Sclerosis in Neurology. Use it to review current recommendation wording,…
View guideline →
Clinical Brief
Anaemia and the new dementia link
Neurology · BBC Health · 07 May 2026
Key Takeaways for Clinical Practice Anaemia has been identified as a newly recognised risk factor for dementia, suggesting haemoglobin levels should be…
View brief →
Clinical Brief
‘My son can now enjoy life’: Children with severe form of epilepsy helped by new drug
Neurology · BBC Health · 04 Mar 2026
Fenfluramine has demonstrated clinical benefit in children with Dravet syndrome, a severe and treatment-resistant form of early-onset epilepsy, with families reporting significant…
View brief →
Guideline
2022 EAN Guidelines on Epilepsy Management in Adults
Neurology · 30 Mar 2026
This EAN guideline addresses 2022 EAN Guidelines on Epilepsy Management in Adults in Neurology. Use it to review current recommendation wording, eligibility…
View guideline →